ASC-J9® suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L. Issue 1 (28th August 2016)

• Record Type: Journal Article
• Authors: Wang, Ronghao; Lin, Wanying; Lin, Changyi; Li, Lei; Sun, Yin; Chang, Chawnshang
• Is Part Of: Cancer letters. Volume 379:Issue 1(2016)
• Page Start: 154
• Page End: 160
• Publication Date: 2016-08-28
• Subjects: PCa -- AR-F876L -- ASC-J9®; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Electronic journals; 616.994
• DOI: 10.1016/j.canlet.2016.05.018
• Languages: English
• ISSNs: 0304-3835

Abstract

Highlights: ASC-J9 ® bears the ability to degrade AR-F876L, one AR mutant that can confer enzalutamide resistance to PCa. ASC-J9 ® suppresses AR-F876L mediated cell proliferation. ASC-J9 ® inhibits AR-F876L mediated cell invasion. Abstract: Androgen deprivation therapy (ADT) with the newly developed powerful anti-androgen enzalutamide (Enz, also known as MDV3100) has promising therapeutic effects to suppress castration resistant prostate cancer (CRPC) and extending patients' lives an extra 4.8 months. However, most Enz therapy eventually fails with the development of Enz resistance. The detailed mechanisms how CRPC develops Enz resistance remain unclear and may involve multiple mechanisms. Among them, the induction of the androgen receptor (AR) mutant AR-F876L in some CRPC patients may represent one driving force that confers Enz resistance. Here, we demonstrate that the AR degradation enhancer, ASC-J9 ®, not only degrades wild-type AR, but also has the ability to target AR-F876L. The consequence of suppressing AR-F876L may then abrogate AR-F876L mediated CRPC cell proliferation and metastasis. Thus, developing ASC-J9 ® as a new therapeutic approach may represent a novel therapy to better suppress CRPC that has already developed Enz resistance.